Uptake Uncertain for Potent New Cholesterol-Lowerer Inclisiran
Inclisiran, a novel small interfering RNA drug that inhibits PCSK9, made its US debut in early 2022 with cautious uptake prospects.
Medscape Medical News
source https://www.medscape.com/viewarticle/967363?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/967363?src=rss
Comments
Post a Comment